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Abstract
Objective: There is a growing interest for matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in plasma as
novel biomarkers in coronary artery disease (CAD). We aimed to identify the sources of MMP-8, MMP-9, TIMP-1 and TIMP-2
among peripheral blood cells and further explore whether gene expression or protein release was altered in patients with
stable angina pectoris (SA).
Methods: In total, plasma MMP-9 was measured in 44 SA patients and 47 healthy controls. From 10 patients and 10 controls,
peripheral blood mononuclear cells (PBMC) and neutrophils were isolated and stimulated ex vivo. MMPs, TIMPs and
myeloperoxidase were measured in plasma and supernatants by ELISA. The corresponding gene expression was measured
by real-time PCR.
Results: Neutrophils were the dominant source of MMP-8 and MMP-9. Upon moderate stimulation with IL-8, the neutrophil
release of MMP-9 was higher in the SA patients compared with controls (p,0.05). In PBMC, the TIMP-1 and MMP-9 mRNA
expression was higher in SA patients compared with controls, p,0.01 and 0.05, respectively. There were no differences in
plasma levels between patients and controls except for TIMP-2, which was lower in patients, p,0.01.
Conclusion: Measurements of MMPs and TIMPs in plasma may be of limited use. Despite similar plasma levels in SA patients
and controls, the leukocyte-derived MMP-9 and TIMP-1 are significantly altered in patients. The findings indicate that the
leukocytes are more prone to release and produce MMP-9 in symptomatic and angiographically verified CAD—a
phenomenon that may have clinical implications in the course of disease.
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Introduction
Matrix metalloproteinases (MMPs) are a family of extracellular
matrix degrading enzymes in which several members, like MMP-8
and MMP-9, are implicated in atherosclerotic plaque development
and atherothrombosis [1–3]. In patients with coronary artery
disease (CAD), MMP-9 in plasma is a predictor of rapid plaque
progression [4] and in-stent restenosis [5]. Serum or plasma levels
of MMP-8 and MMP-9 are also associated with cardiovascular
outcome in patients with an established diagnosis of CAD [6–10].
In cross-sectional studies, transient elevations of MMP-8 or MMP-
9 have been associated mainly with acute coronary syndrome [11–
14]. Studies of patients with clinically stable CAD have, on the
other hand, shown inconsistent results, in particular for MMP-9.
Some have shown increased levels of MMP-8 and MMP-9 in
patients with stable angina (SA) when compared with healthy
individuals [11–13,15–19] while others have not shown any
differences [12–14,20].
There may be several cellular sources of MMP-8 and MMP-9 in
plasma. Circulating levels are believed to reflect, at least in part,
the release of MMPs from cells in the arterial wall, such as smooth
muscle cells and macrophages. Peripheral blood cells are another
potential source of MMPs in plasma. The higher levels of MMP-8
and MMP-9 in serum compared to plasma are assumed to result
from the release by neutrophils during the coagulation process in
the serum tube [21,22]. In neutrophils, MMP-8 and MMP-9 are
synthesized during the late stage maturation process in the bone
marrow and thereafter stored in specific and gelatinase granules
until needed. In particular, MMP-8 is known as the ‘‘neutrophil
collagenase’’ [23]. It has also been shown that several MMPs
including MMP-8 and MMP-9 are constitutively expressed by the
mononuclear cells in peripheral blood [24,25]. An increased
expression and/or release of MMPs have been associated with a
primed or activated state of leukocytes and may play a key role for
the adhesion and transmigration into the arterial wall.
Tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2
are the main endogenous regulators of MMP-8 and MMP-9
activity. An imbalance between TIMPs and MMPs is believed to
be crucial for the maintenance of plaque stability and interestingly,
reduced amounts of TIMP-1 and TIMP-2 have been reported in
human unstable plaques compared to stable plaques [26,27]. A
few clinical studies have shown increased plasma levels of TIMP-1
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healthy controls [14,16,17]. Similarly, studies regarding the
clinical association of circulating TIMP-2 levels have shown
contradictory results [13,15,16]. According to the literature,
cellular sources of TIMP-1 and TIMP-2 may include several cell
types, such as smooth muscle cells, macrophages and circulating
mononuclear cells [24,28].
There is a growing interest for MMPs and TIMPs as both
diagnostic markers and therapeutic targets in CAD. However, the
measurements of plasma levels may be insufficient to detect
differences of potential clinical relevance. This has been illustrated
in previous studies of CAD patients showing an increased
expression of MMP-9 in neutrophils [20] and monocytes [14]
without any concomitant changes in plasma levels. The aim of the
present study was to identify the sources of MMP-8, MMP-9,
TIMP-1 and TIMP-2 among peripheral blood cells. We further
hypothesised that the gene expression or protein release was
altered in patients with symptomatic and angiographically verified
CAD compared with healthy individuals.
Methods
Ethics Statement
Written informed consent was obtained from study participants
and the research protocol was approved by the Ethical Review
Board of Linko ¨ping University. The study was conducted in
accordance with the ethical guidelines of Declaration of Helsinki
(Linko ¨ping University M242-08).
Subjects
Forty-four SA patients referred for elective coronary angiogra-
phy at the Department of Cardiology, Linko ¨ping University
Hospital, Sweden were included in the study. They had clinical
evidence of Canadian Cardiovascular Society class II and III
[29]and positive exercise tests or myocardial scintigrams. The
diagnosis of CAD was angiographically verified in all patients.
Exclusion criteria were severe heart failure, immunologic disor-
ders, neoplastic disease, evidence of acute or recent (,2 months)
infection, recent major trauma, surgery or revascularization
procedure, or treatment with immunosuppressive or anti-inflam-
matory agents (except low-dose aspirin). Forty-seven clinically
healthy age and sex matched controls were randomly selected
from a population register representing the hospital recruitment
area. None of them were taking any medication. Heparinized
venous peripheral blood and serum with activation clot was
collected in the morning after a fasting for 12 h and in patients,
always prior to coronary angiography.
Preparation and stimulation of peripheral blood
mononuclear cells and neutrophils
For the ex vivo assays, a subgroup of 10 patients was randomly
selected from the large group and matched with 10 controls.
Peripheral blood mononuclear cells (PBMCs) and granulocytes,
predominantly constituted by neutrophils, were separated from
heparinised whole blood by density centrifugation as previously
described [30]. In short, freshly drawn heparinized blood was
layered on top of Lymphoprep
TM and Polymorphprep
TM (Axis-
Shield PoC AS, Oslo, Norway), and centrifuged in a swing-out
centrifuge (4206g, 40 min, room temperature (RT)), thus
producing one band of PBMCs and one of neutrophils.
The PBMCs were collected and washed in phosphate buffered
saline (PBS) with 0.1% fetal bovine serum (FBS) (PAA Labora-
tories GmbH, Pasching, Austria) by centrifugation (4006g,
10 min, 4uC) twice. The cells were resuspended in RPMI-1640
media supplemented with L-glutamine (Gibco by Invitrogen,
Carlsbad, CA, USA), 10% FBS, 100 U/ml penicillin and 100 mg/
ml streptomycin (Gibco by Invitrogen, Carlsbad, CA, USA) to a
concentration of 5610
6 cells/ml. PBMCs were stimulated with
phorbol 12-myristate 13-acetate (PMA; Sigma -Aldrich Corpora-
tion, St Louis, MO, USA) 25 ng/ml and ionomycin (Calbiochem,
Darmstadt, Germany) 1 mg/ml in 37uC, 5% CO2 for 4 hours.
The cells were centrifuged for 3006g, 5 min and the supernatant
was collected for enzyme-linked immunosorbent assay (ELISA).
The cells were then further washed 3 times in PBS by
centrifugation 3006g, 5 min, RT and collected for real-time
polymerase chain reaction (PCR) analyses. Cells and supernatants
were stored in 270uC until analysis.
The neutrophils were collected, washed and resuspended in
PBS and NaCl and concentrated by a short centrifugation. The
erythrocytes were lysed by a hypotonic solution and the
neutrophils were washed with Krebs-Ringers glucose (KRG)
without Ca
2+ (0.1 mol/l NaCl, 5 mmol/l KCl, 1 mmol/l MgSO4,
2 mmol/l KH2PO4, 8 mmol/l Na2HPO4 and 10 mmol/l glu-
cose). The neutrophils were then resuspended in RPMI-1640 with
L-glutamine, 10% FBS and 100 U/ml penicillin 100 mg/ml
streptomycin to a concentration of 5610
6 cells/ml and kept on
ice. They were stimulated with PMA 25 ng/ml or interleukin (IL)-
8 (Sigma -Aldrich Corporation, St Louis, MO, USA 10 ng/ml for
10 min in a 37uC water bath. The cells were then centrifuged for
3006g, 5 min, RT and the supernatant was collected for ELISA
analyses. The neutrophils were further washed 3 times in PBS by
centrifugation for 3006g, 5 min, RT and collected for real-time
PCR analyses. Cells and supernatants were stored in 270uC until
analysis.
Determination of MMP-8, MMP-9, TIMP-1, TIMP-2 and
myeloperoxidase (MPO) levels by ELISA
MMP-8, MMP-9, TIMP-1, TIMP-2 and myeloperoxidase
(MPO) were measured in heparinized plasma, serum with
activation clot and cell supernatants by ELISA (QuantikineH
immunoassay, R&D systems, Minnneapolis, MN, USA). The
MMP-8 ELISA measures both latent and active forms of the
enzyme while the MMP-9 ELISA measures pro-MMP-9, active
MMP-9 and MMP-9/TIMP-1 complexes. The lower limits of
detection for MMP-8, MMP-9, TIMP-1, TIMP-2 and MPO were
0.02, 0.156, 0.08, 0.011 and 0.1 ng/ml, respectively. The
interassay coefficients of variation (CV) were always ,7%.
Real-time PCR
Total RNA was isolated from separate fractions of PBMCs and
neutrophils with RNeasy mini kit (Qiagen, Hilden, Germany)
according to manufacturer’s instructions. 0.73 mg RNA was
reversed transcribed with high capacity cDNA reverse transcrip-
tion kit with an RNAse inhibitor (Applied Biosystems, Foster City,
CA, USA) according to manufacturer’s instructions. cDNA (1 mL)
was amplified by RT-PCR reactions with 16 TaqMan Fast
Universal PCR Mastermix (Applied Biosystems, Foster City, CA,
USA) in 96-well plates on an ABI 7500 Sequence Detector with
SDS 1.3.1 software. The following TaqManH Gene Expression
Assay kits (Applied Biosystems) were used: MMP-8, Hs01-
029057_m1; MMP-9, Hs00957562_m1; TIMP-1, Hs00171-
558_m1; TIMP-2, Hs00234278_m1. Eukaryotic 18S rRNA (Part
number: 4352930E) with an amplicon length of 187 bp served as
endogenous control. The amount of expressed gene was calculated
relative to the amount of rRNA in each sample. Standards were
used to create a standard curve in each run according to the
standard curve method in user bulletin no 2 (Applied Biosystem,
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maximum deviation of 15% was allowed.
Statistics
PASW Statistics 18 was used for statistical analyses. For clinical
and laboratory characteristics, data are presented as median (inter-
quartile range). The statistical significance of any difference
between patients and controls was tested by using Mann-Whitney
U-test. Chi-square test was used for nominal data. Differences
within the groups were analyzed using Wilcoxon signed-rank tests.
Correlation analysis was performed using Spearman’s rank
correlation method. A p-value , 0.05 was considered statistically
significant while a p-value , 0.1 was considered a trend.
Results
Clinical and laboratory characteristics of subjects
Clinical characteristics and laboratory variables of all patients
and controls are outlined in Table 1. The waist circumference was
significantly higher, and there were more current smokers among
patients. The total number of white blood cells was also
significantly increased in the patient group depending on a
significant increase in neutrophils, but not PBMCs. All patients
were using low-dose aspirin and various combinations of nitrates,
beta-blockers and/or calcium antagonists. Seventy-one % of them
had hypertension and 16% had diabetes. The majority of the
patients (82%) had a normal left ventricular systolic function, while
14% had a mild and 4% had a severe ventricular dysfunction.
Twenty-four % of the patients had a history of prior myocardial
infarction and/or coronary revascularization. Eighty-six % of the
patients were on long-term therapy with statin. The characteristics
of the 10 patients and 10 controls in the subpopulations selected
for ex vivo studies are shown in Table 2.
MMP-8 and MMP-9
The levels of MMP-8 and MMP-9 in plasma, serum and cell
supernatants from neutrophils are presented in Table 3. The levels
in plasma did not differ between patients and controls, neither did
the serum levels. The spontaneous release of MMP-9 into the
neutrophil supernatant tended to be higher in patients compared
with controls and became statistically significant after IL-8
stimulation. However, after PMA stimulation the neutrophil
release of MMP-9 was significantly lower in the patient group.
The release of MMP-9 from both untreated and stimulated PBMC
was negligible (data not shown). The release of MMP-8 was similar
in non-treated and IL-8-treated neutrophils, but increased
markedly upon PMA-stimulation in both patients and controls.
MMP-8 in PBMC or platelet supernatants was not detectable
(data not shown).
TIMP-1 and TIMP-2
The levels of TIMP-1 and TIMP-2 in plasma, serum and cell
supernatants are presented in Table 4. The levels of TIMP-1 in
plasma or serum did not differ between patients and controls.
TIMP-1 was not detectable in neutrophil supernatants. In PBMC
supernatants, it was detected after 19 h in culture without any
significant differences between patients and controls (data not
shown). The plasma levels of TIMP-2 were significantly lower in
patients compared with controls. The serum levels of TIMP-2 also
tended to be lower in the patient group. Upon IL-8 or PMA
stimulation, the release of TIMP-2 from neutrophils increased by a
similar extent in patients and controls. The release of TIMP-2
from PBMC was similar in patients and controls regardless of cell
stimulation.
MPO
The levels of MPO in plasma, serum and cell supernatants are
presented in Table 5. The levels of MPO in plasma and serum did
not differ between patients and controls. In SA patients, MPO was
significantly higher in serum than in plasma, whereas in controls,
the serum and plasma levels were similar. The spontaneous release
of MPO from neutrophils tended to be higher in patients than in
controls. Upon PMA stimulation, the release of MPO increased
significantly in the control group, whereas there was no statistically
significant increase in the patient group.
Table 1. Characteristics of patients with stable angina
pectoris (SA) and controls in the whole cohort.
Patients Controls p
Age, years 63 (57–71) 63 (58–71) NS
Male/female 34/10 34/13 NS
Current smokers, n (%) 8 (18) 1 (2) ,0.05
Waist circumference, cm 101 (94–107) 95 (88–98) ,0.001
Total cholesterol, mmol/l 4.6 (4.0–5.4) 5.7 (4.9–6.6) ,0.001
LDL cholesterol, mmol/l 2.4 (2.1–3.4) 3.6 (2.8–4.2) ,0.001
HDL cholesterol, mmol/l 1.2 (1.1–1.4) 1.5 (1.2–1.7) ,0.001
Triglycerides, mmol/l 1.4 (1.1–1.7) 1.1 (0.93–1.6) ,0.05
Creatinine, mmol/l 92 (83–104) 88 (78–99) NS
White blood cells, cell/ml 6600 (5100–8400) 5500 (4600–6400) 0.001
Diabetes, n (%) 7(16) 0 (0) 0,005
Hypertension, n (%) 32 (73) 0 (0) ,0,001
Statin, long-term
treatment, n (%)
36 (86) 0 (0) ,0,001
Data are given as median (inter-quartile range).
doi:10.1371/journal.pone.0019340.t001
Table 2. Characteristics of the subpopulations of patients
with stable angina pectoris (SA) and controls selected for the
ex vivo assays.
Patients Controls p
Age, years 60 (56–68) 63 (57–69) NS
Male/female 6/4 6/4 NS
Current smokers, n (%) 3 (30) 0 (0) NS
Waist circumference, cm 101 (95–103) 95 (88–98) 0,062
Total cholesterol, mmol/l 4,2 (3,8–4,3) 6,3 (5,5–6,8) 0,001
LDL cholesterol, mmol/l 2,3 (1,8–2,5) 3,9 (3,4–4,7) 0,002
HDL cholesterol, mmol/l 1,1 (1,1–1,4) 1,7 (1,5–1,8) 0,01
Triglycerides, mmol/l 1,4 (1–1,5) 1,2 (0,97–1,9) NS
Creatinine, mmol/l 83 (67–89) 73 (57–82) NS
White blood cells, cell/ml 7100 (5400–8600) 5700 (4700–6400) NS
Diabetes, n (%) 3 (30) 0 (0) NS
Hypertension, n (%) 8 (80) 0 (0) 0,001
Statin, long-term treatment
n( % )
10 (100) 0 (0) ,0,001
Data are given as median (inter-quartile range).
doi:10.1371/journal.pone.0019340.t002
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The mRNA expression of MMP-9 and TIMP-1 in PBMC (left
untreated for 4 h) was significantly higher in patients compared
with controls (Figure 1a and b) while the TIMP-2 mRNA levels in
PBMC tended to be increased in the patient group (Figure 1c).
After 4 h stimulation, the mRNA expression of MMP-9 and
TIMP-1 in PBMC increased but without any significant
differences between patients and controls (data not shown). On
the other hand, PBMC from controls showed an increase in
TIMP-2 mRNA after 4 h stimulation reaching similar levels as
PBMC from patients. In neutrophils, the mRNA expression of
MMP-9, TIMP-1 and TIMP-2 did not differ between patients and
controls neither before nor after stimulation with IL-8 or PMA
(data not shown). MMP-8 mRNA was not detectable in either
neutrophils or PBMC.
Correlations
The levels of MMP-8 and MMP-9 in plasma did not correlate
with any clinical characteristics, such as waist circumference or
smoking; neither did the plasma levels correlate with lipid or
creatinine levels. MMP-8 and MMP-9 in plasma were correlated
to the white blood cell count, r=0.24 and 0.30 respectively,
p,0.05. In addition, MMP-9 was correlated with the neutrophil
count (r=0.28, p,0.05), but not with the PBMC count. In
plasma, MMP-8 and MMP-9 were intercorrelated (r=0.87,
p,0.001) and they were also highly correlated to MPO (both
r=0.80, p,0.001). TIMP-1 in plasma did not show any
significant correlations with clinical or laboratory parameters
whereas TIMP-2 in plasma was inversely correlated to waist
circumference (r=20.21, p,0.05) and positively related to HDL
cholesterol levels (r=0.22, p,0.05). HDL levels were inversely
Table 3. MMP-8 and MMP-9 levels (ng/ml) in plasma, serum and neutrophil supernatants.
n (pat/co) Patients Controls p
MMP-8 Plasma 44/47 3.1 (1.5–3.5) 3.1 (2.2–5.7) NS
Serum 10/10 12.4 (5.2–39) 8.1 (5.7–19) NS
Spontaneous release 10/10 8.5 (4.6–10.4) 7.3 (5.9–9) NS
IL-8-induced release 10/10 10.0 (5.7–15.4) 8.9 (7–10.3) NS
PMA-induced release 10/10 142 (96–192) 174 (133–190) NS
MMP-9 Plasma 44/47 67 (38–107) 53 (43–85) NS
Serum 10/10 438 (275–1049) 388 (215–608) NS
Spontaneous release 10/10 126 (100–184) 93 (90–142) 0.07
IL-8-induced release 10/10 306 (214–333) 208 (175–289) ,0.05
PMA-induced release 10/10 1261 (1104–1441) 1557 (1382–1708) ,0.05
Data are given as median (inter-quartile range).
doi:10.1371/journal.pone.0019340.t003
Table 4. TIMP-1 and TIMP-2 levels (ng/ml) in plasma, serum, neutrophil and PBMC supernatants.
n (pat/co) Patients Controls p
TIMP-1 Plasma 44/47 87 (78–95) 92 (80–103) NS
Serum 10/10 193 (168–213) 180 (151–191) NS
Neutrophil release, untreated 10/10 ND ND
Neutrophil release, IL-8 10/10 ND ND
Neutrophil release, PMA 10/10 ND ND
PBMC release, untreated 4 h 10/10 ND ND
PBMC release, PMA 4 h 10/10 ND ND
TIMP-2 Plasma 44/47 70 (65–77) 79 (72–83) ,0.01
Serum 10/10 77 (72–86) 85 (80–87) 0.08
Neutrophil release, untreated 10/10 1.3 (1.2–1.5) 1.3 (1–1.4) NS
Neutrophil release, IL-8 10/10 2.4 (2–2.9) 2.2 (2–2.4) NS
Neutrophil release, PMA 10/10 10.2 (8–11.6) 11.1 (10–11.7) NS
PBMC release, untreated 4 h 10/10 1.0 (0.8–1.2) 1.0 (0.9–1.2) NS
PBMC release, PMA 4 h 10/10 1.5 (1.1–1.8) 1.5 (1.3–1.7) NS
ND=Non Detectable.
Data are given as median (i-q range).
doi:10.1371/journal.pone.0019340.t004
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both variables were entered into a multiple linear regression
model, their significant correlation to TIMP-2 was lost. Patients
and controls were grouped together for all correlation analyses.
Discussion
Among peripheral blood cells, the neutrophils were found to be
a dominant source of MMP-8 and MMP-9, as assessed by short-
term release assays. This was not an unexpected finding since
previous work has shown that neutrophils are responsible for the
rapid release of MMPs that occurs in blood upon stimulation with
endotoxin or proinflammatory cytokines [31–33]. However, in SA
patients, the neutrophils released more MMP-9 in response to IL-8
than neutrophils from controls. These results are in line with a
study by Tayebjee et al [20] who showed increased amounts of
intracellular neutrophil MMP-9, as assessed by flow cytometry, in
patients with SA compared with healthy controls. Since the
neutrophil release of MMP-9 is assumed to serve as a sensitive and
early marker of neutrophil activation [32], the findings may
indicate a persistent neutrophil activation in the SA patients. The
appropriate use of MMP-9 as a neutrophil activation marker was
strengthened by its high correlation to MPO, another principal
enzyme released upon neutrophil activation [31]. In a previous
study, we also demonstrated an increased number of circulating
neutrophil-platelet aggregates in patients with SA which further
supports the presence of activated neutrophils in CAD [34]. On
the other hand, we and others have demonstrated an impaired
neutrophil response to intense stimulation in SA patients including
a reduced capacity to generate reactive oxygen species in response
to strong stimuli [35,36]. IL-8 may be regarded as a physiological
stimulator of neutrophils while compounds like PMA are more
likely to trigger maximal degranulation. When the neutrophils
from patients were stimulated with PMA in the present study, they
released significantly lower amounts of MMP-9 compared with
controls. The extensive statin treatment in stable CAD patients
may at least partly explain the suboptimal response of neutrophils
to a strong stimulus. In a randomized clinical study, the endotoxin-
induced increase in neutrophil oxidative burst was markedly
attenuated by simvastatin [37]. The treatment with low-dose
aspirin may also exert suppressive effects on neutrophils. Aspirin
has been shown to attenuate the inflammatory response in
neutrophils, e.g. by decreasing the transmigration capacity and
inhibiting the delayed apoptosis of cells [38,39].
In unstimulated PBMC, the mRNA expression of MMP-9 was
found to be significantly increased in SA patients compared with
controls. The expression of MMPs in human mononuclear cell
subsets has been systematically analyzed in a previous study by
Bar-Or et al [24] showing that MMP-9 mRNA was particularly
abundant in monocytes compared with B and T cells. However,
our findings of upregulated MMP-9 mRNA in SA patients is not in
agreement with two recent studies of CAD patients. When
Table 5. MPO levels (ng/ml) in plasma, serum and neutrophil
supernatants.
n (pat/co) Patients Controls p
MPO Plasma 44/47 325 (196–494) 351 (265–486) NS
Serum 10/10 580 (316–909)
a 338 (193–468) NS
Spontaneous
release
10/10 1237 (1140–1850) 1046 (858) 0.09
PMA-induced
release
10/10 1452 (1270–1950) 1526 (891–1740)
b NS
ap,0.01 compared with plasma in patients.
bp,0.001 compared with spontaneous release in neutrophils from controls.
Data are given as median (i-q range).
doi:10.1371/journal.pone.0019340.t005
Figure 1. Gene expression of MMP-9 and TIMP-1 in PBMC.
MMP-9 (A) and TIMP-1 (B) mRNA expression was higher in PBMC of CAD
patients compared with controls (p,0.05 and 0.01, respectively). The
expression of TIMP-2 (C) tended to be increased in PBMC of patients
(p=0.07).
doi:10.1371/journal.pone.0019340.g001
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unstimulated monocytes, they found no differences between SA
patients (n=18) and controls (n=16) but a significant increase in
patients with acute coronary syndrome. Likewise, Fang et al
[25]cultured PBMC for 24 h and reported no difference in MMP-
9 mRNA between SA patients (n=8) and controls (n=12) but a 2-
fold increase in patients with acute coronary syndrome. One
possible reason for our discrepant results regarding SA patients
may be an increased ischemic burden in our patient group, i.e.
they were all referred for coronary angiography due to disabling
angina pectoris. In vitro, a variety of proinflammatory and
atherogenic factors including cytokines and oxidized low-density
lipoproteins has been shown to upregulate MMP-9 expression in
monocytes [24,40]. Our findings suggest that this may be relevant
also in vivo under clinically stable conditions.
Not only MMP-9 mRNA, but also TIMP-1 mRNA, was
increased in untreated PBMC from patients. Likewise, the
transcript levels of TIMP-2 tended to be increased in the PBMC
of patients. As previously shown, TIMP-1 and, to a lesser extent
TIMP-2, is constitutively expressed and secreted by monocytes
[14,24,28,41]. The concomitant increase of MMP-9 and TIMP
mRNA in PBMC from patients was not a surprising finding since
the expression of proteases in many physiological settings goes
along with the simultaneous expression of their inhibitors. Upon
stimulation with PMA, the induction of MMP-9 synthesis by
mononuclear cells has been shown to be accompanied by
production of TIMP-1 [28]. Despite increased mRNA expression,
only negligible amounts of MMPs and TIMPs were released by
PBMC upon 4 h treatment with PMA. PMA has been shown to be
a potent inducer of MMP and TIMP in experimental studies of
blood-derived mononuclear cells [28,41]. Still, it is possible that we
did not use the appropriate stimulation conditions to allow protein
secretion.
In agreement with a number of previous studies [12–14,20],
there were no significant differences in circulating levels of MMP-9
between SA patients and controls. Neither did the plasma or
serum levels of MMP-8 differ between patients and controls which
is in contrast to previous studies [11,18] that have shown raised
plasma MMP-8 in SA patients. As expected, serum levels were
markedly increased compared with plasma levels probably due to
an extensive degranulation of neutrophils in the serum sample. In
accordance with this, the time-dependent release of other
neutrophil mediators, such as leukotriene B4 has been seen to
occur during serum preparation [42].
The serum and plasma concentrations of TIMP-1 were similar
in patients and controls while TIMP-2 in plasma was significantly
lower in the patient group. In line with our results, two earlier
reports on TIMP-2 have shown lower levels in SA patients
compared with controls [13,15] while Tayebjee et al [16]
demonstrated increased levels of TIMP-2 in patients. Compared
with TIMP-1, TIMP-2 showed a significant relationship to
metabolic factors like waist circumference and HDL concentra-
tions. A differential relationship of TIMP-1 and TIMP-2 to
circulating markers of inflammation and hemostasis has been
reported previously [43]. The imbalance between MMP-9, TIMP-
1 and TIMP-2 expression in the atherosclerotic plaque may be
crucial for its transformation into an unstable, rupture-prone state.
Interestingly, TIMP-2 has been shown to be more effective than
TIMP-1 in inhibiting MMP-9 [44]. We can only speculate that the
plasma levels reflect, at least in part, the levels of TIMP-2 in
atherosclerotic tissue. In a previous study on patients who had
undergone successful carotid artery endarterectomy, a decreased
production of TIMP-2 in unstable carotid lesions was associated
with decreased levels in plasma [26].
There are certain limitations of our study. The study population
was small and results should therefore be interpreted with caution,
neither is it possible to evaluate the prognostic significance of the
results. The control group was a clinically healthy population
without any chronic medication. However, they were not
angiographically examined and the possibility of subclincal
atherosclerosis can not be ruled out.
To conclude, our findings indicate that measurements of MMPs
and TIMPs in plasma may be of limited use in the evaluation of
inflammatory status in CAD patients. Despite ‘‘normal’’ plasma
levels, the leukocyte-derived MMP-9 and TIMP-1 were signifi-
cantly altered in patients with symptomatic and angiographically
verified CAD. First, the neutrophils released significantly more
MMP-9 upon moderate stimulation which indicates the presence
of neutrophils that are more prone to stimulation. Second, the
increased mRNA levels of MMP-9 and TIMP-1 in PBMC suggest
that these cells might also be preactivated with an increased
transmigratory capacity. However, so far we can only theorize
about the effects of increased leukocyte-derived MMP-9. Its
potential clinical implications remain to be clarified in future
studies.
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